Tag Archives: PMPRB

Mark Warner was interviewed on Global News Radio 640 Toronto about the delay by Pfizer in delivering COVID19 vaccines to Canada against the backdrop of pharmaceutical industry concerns with Canadian intellectual property, tax and drug pricing policies. (January 20, 2021) Mr. Warner is a Canadian and U.S. lawyer who has practiced in Toronto, Washington, DC and New York and has advised governments on trade policy and trade negotiations and previously worked on trade and competition issues as counsel in the OECD Trade Directorate.

Mr. Warner has assisted pharmaceutical clients in the global distribution of HIV / AIDS anti-retroviral drugs and the development of innovative patient access programs in the developing world, advised a U.S.-based pharmaceutical company and its French and South African subsidiaries in a cartel investigation involving 11 leading global Pharmaceutical companies in South Africa and advised a U.S.-based pharmaceutical company on competition law issues relating to the distribution of various nuclear medicine imaging agents in Canada. Mr. Warner was Legal Director of the Ontario Ministry of Economic Development & Trade and advised Ontario on the negotiations of the Canada-EU Trade Agreement (CETA) including on IP, patent litigation and drug reimbursement issues and on economic development, research and innovation grants and loans to corporations, including leading global pharmaceutical companies for research, manufacture and clinical trial projects. As Legal Director of the Ontario Ministry of Research and Innovation, Mr. Warner also led Ontario’s legal team in creating the $250 million Ontario Emerging Technologies Fund with an emphasis on life-sciences companies, drafted funding agreements, including for the Ontario Research Fund and Ontario Brain Institute, and advised on legal and corporate governance issues in the formation of Clinical Trials Ontario.

In addition, Mr. Warner, led the Province’s legal team for the insolvency / restructuring of General Motors and Chrysler in the difficult context of the 2008-2009 Recession.

Mark Warner was interviewed on the Canada Talks SiriusXM 167 Arlene Bynun Show about the Canadian Government’s proposals to delete Switzerland and the United States from index of countries used to set drug prices in Canada. (August 12, 2019) These proposals have implications for President Trump’s proposals to facilitate the import of certain drugs from Canada, and are similar to proposals under discussion between President Trump and Congress and may factor in the ongoing efforts to pass the United States Mexico Canada Agreement (USMCA) / (NAFTA 2.0). Mr. Warner was Legal Director of the Ontario Ministry of Economic Development & Trade and advised Ontario in the negotiation of the Canada – EU Trade Agreement (CETA) including on drug pricing and patent appeals and on other trade and investment negotiation and dispute settlement matters including NAFTA . Mr. Warner, a Canadian and U.S. lawyer, has advised pharmaceutical companies on pricing, distribution and other competition and trade matters. Mr. Warner has also governments on trade policy and trade negotiations and previously worked on trade and competition issues as counsel in the OECD Trade Directorate.

Mark Warner was quoted in The Philadelphia Inquirer about how new Canadian drug pricing policies impact on the renegotiation of the North American Free Trade Agreement (NAFTA). (December 22, 2017) Mr. Warner was Legal Director of the Ontario Ministry of Economic Development & Trade and advised Ontario in the negotiation of the Canada – EU Trade Agreement (CETA) including on drug pricing and patent appeals and on other trade and investment negotiation and dispute settlement matters including NAFTA . Mr. Warner, a Canadian and U.S. lawyer, has advised pharmaceutical companies on pricing, distribution and other competition and trade matters. Mr. Warner has also governments on trade policy and trade negotiations and previously worked on trade and competition issues as counsel in the OECD Trade Directorate.